Market capitalization | $4.45m |
Enterprise Value | $-17.62m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 3.69 |
P/B ratio (TTM) P/B ratio | 0.35 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-6.76m |
Free Cash Flow (TTM) Free Cash Flow | $-4.78m |
Cash position | $22.07m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Synaptogenix Inc:
1 Analyst has issued a forecast Synaptogenix Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.01 -0.01 |
0%
0%
|
|
EBITDA | -6.76 -6.76 |
44%
44%
|
EBIT (Operating Income) EBIT | -6.76 -6.76 |
44%
44%
|
Net Profit | -8.22 -8.22 |
1,368%
1,368%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Synaptogenix, Inc. operates as a biopharmaceutical company. It develops a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease, which is in the clinical testing stage. The firm also evaluates potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions. The company was founded on October 31, 2012 and is headquartered in New York, NY.
Head office | United States |
CEO | Alan Tuchman |
Employees | 8 |
Founded | 2012 |
Website | www.synaptogen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.